September 26, 2021 -- Enrich Therapeutics is developing a desktop static cell isolation technology that can separate clones to accelerate therapeutic discovery. We spoke with Dong Wang, who is co-founder, president, and chief operating officer of Enrich Therapeutics, as part of our coverage of the competition.
Enrich Therapeutics’ isolation technology does not involve forcing cells through a sorting process (which is a requirement for dynamic cell isolation). According to Wang, the company’s platform allows cells to settle in culture plates. This advantage allows cells to maintain their native state, and it is helpful for observation studies and when investigating cell-to-cell interactions. Importantly, the technology enables the capture of cells regardless of the cell culture method (adherent or suspension) used.
The technology uses scalable, inexpensive but highly precise liquid crystal display to characterize irreversible chemical reactions that capture and protect individual cells with user-defined criteria. Wang explained that the platform’s isolation accuracy is very high; the entire process is visible on the instrument’s integrated microscope.
Enrich Therapeutics is one of 10 semifinalists that have the chance to win $200,000 in cash prizes in the BioTools Innovator accelerator contest, with the list of semifinalists released in late July. All semifinalists are assigned a mentor and will complete a curated curriculum designed to help them secure additional funding and elevate their companies. The field will be narrowed to four companies in early October. The four finalists will present at a live finale on October 14, 2021, where the audience will help decide the winner.
Stay tuned and follow along as we get a behind-the-scenes look at these companies as they race toward the finish!
Note: The BioTools Innovator accelerator contest is sponsored by Research Corporation Technologies and BroadOak Capital Partners, investors in ScienceBoard.net's parent company, Science and Medicine Group.